Targets › ATP1B2
7 programs from 7 companies in 7 trials: 3 Phase 2, 3 Phase 1, 1 Phase 4; Cardiovascular, Oncology, Gastroenterology; next expected readout Dec 2026.
This is the non-catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. The exact function of the beta-2 subunit is not known.; FUNCTION: Mediates cell adhesion of neurons and astrocytes, and promotes neurite outgrowth. (UniProt, P14415)
Open in Phaseline: the race on ATP1B2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital General de Agudos "Dr. Cosme Argerich" | Digoxin Sodium/potassium-transporting ATPase inhibitor | Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2 | Phase 4 | Acute Heart Failure (AHF) | Dec 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | Digoxin Sodium/potassium-transporting ATPase inhibitor | Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2 | Phase 2 | Medulloblastoma | Feb 2027 |
| Seismic Pharmaceuticals Operations | istaroxime Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator | Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2 | Phase 2 | Cardiogenic Shock | Dec 2028 |
| Yale University | Digoxin Sodium/potassium-transporting ATPase inhibitor | Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2 | Phase 2 | NASH | Jan 2029 |
| Danae Hamouda, MD | Digoxin Sodium/potassium-transporting ATPase inhibitor | Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2 | Phase 1 | Advanced Pancreatic Cancer | Dec 2026 |
| State University of New York - Downstate Medical Center | Digoxin Sodium/potassium-transporting ATPase inhibitor | Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2 | Phase 1 | Pancreatic Cancer Metastatic | Dec 2028 |
| Windtree Therapeutics | Istaroxime Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator | Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2 | Phase 1 | Cardiogenic Shock | – |
Cardiogenic Shock (2) Acute Heart Failure (AHF) (1) Medulloblastoma (1) Advanced Pancreatic Cancer (1) Pancreatic Cancer Metastatic (1) NASH (1)
small molecule (7)
Seismic Pharmaceuticals Operations (1) Hospital General de Agudos "Dr. Cosme Argerich" (1) Windtree Therapeutics (1) H. Lee Moffitt Cancer Center and Research Institute (1) Danae Hamouda, MD (1) State University of New York - Downstate Medical Center (1) Yale University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.